Table of Contents
Atorvastatin is a widely used medication in the management of hypercholesterolemia and cardiovascular risk reduction. It belongs to the class of drugs known as statins, which are HMG-CoA reductase inhibitors.
Mechanism of Action of Atorvastatin
Atorvastatin exerts its effect by inhibiting the enzyme HMG-CoA reductase, a key enzyme in the mevalonate pathway responsible for cholesterol synthesis in the liver. This inhibition leads to decreased production of mevalonate, a precursor to cholesterol.
As a result, the liver increases the expression of LDL receptors on its surface, which enhances the clearance of low-density lipoprotein (LDL) cholesterol from the bloodstream. This dual action effectively lowers plasma LDL cholesterol levels.
Biochemical Pathway Impact
The inhibition of HMG-CoA reductase by atorvastatin causes a reduction in the synthesis of cholesterol within hepatocytes. This decrease triggers a compensatory increase in LDL receptor activity, further reducing circulating LDL cholesterol.
Normal Cholesterol Synthesis Pathway
- Acetyl-CoA converts to HMG-CoA
- HMG-CoA is converted to mevalonate by HMG-CoA reductase
- Mevalonate leads to cholesterol synthesis
Effect of Atorvastatin
- Inhibits HMG-CoA reductase
- Reduces mevalonate production
- Decreases cholesterol synthesis
- Upregulates LDL receptor expression
- Increases clearance of LDL cholesterol
Clinical Significance
By lowering LDL cholesterol, atorvastatin significantly reduces the risk of atherosclerotic cardiovascular disease, including myocardial infarction and stroke. It is often prescribed as part of a comprehensive lipid management plan.
Understanding its mechanism helps clinicians tailor therapy and predict patient response, optimizing cardiovascular outcomes.